Destructive pneumonias in children

Abstract

Purpose. A complicated acute destructive pneumonia is one of the most severe purulent and septic diseases in children. The issue is pressing as a high level of lungs and pleura purulent morbidity among different age groups has been preserved till now. Materials and methods. The article reviews Russian and foreign literature addressing the issues of destructive pneumonia epidemiology, reviewing etiological aspects of the disease and analyzing the most frequent pathological agents which result in destructive pneumonia. Moreover, the authors’ views on pathogenesis and pathomorphology of this disease and its clinical signs are presented. Effectiveness of diagnostic research methods in diagnosis verification is comparatively assessed. A special attention is given to various methods of antibacterial therapy and prevention of this severe disease. Conclusions. The authors conclude that destructive pneumonia is a severe complication of pneumonia in children. S. pneumoniae and S. Aureus refer to its basic causative agents. Further studies need to establish the host-pathogen interaction, improve the microbiological diagnosis and optimize conservative and surgical treatment.

Keywords

destructive pneumonia / children

References

[1] Грона В. Н., Сопов Г. А.. Клинические проявления, диагностика и лечение бактериальной деструкции легких у детей. Журнал Здоровье ребенка. 2008;1(10):43–46. http://www.mif-ua.com/archive/article_print/4346

[2] Разумовский, А.Ю., Аллаберганов К. О., Рачков В. Е., Алхасов М. Б. Оценка эффективности различных методов диагностики острых гнойно-воспалительных заболеваний легких и плевры у детей. Педиатрия. 2006; (1): 57–59

[3] Хаспеков Д. В., Ольхова Е. Б., Топилин О. Г., Сафин Д. А., Ткаченко Н. В. Соколов Ю. Ю. Современные методы диагностики и лечения деструкивиной пневмонии у детей. Российский вестник детской хирургии анестезиологии и реаниматологии. 2015;5(2): 7–12

[4] Griffin M. R., Zhu Y., Moore M. R., Whitney C. G., Grijalva C. G. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N. Engl. J. Med. 2013;369:155–63. DOI: 10.1056/NEJMoa1209165

[5] Jardine A., Menzies R. I., McIntyre P. B. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr. Infect. Dis. J. 2010; 29:607–12. DOI: 10.1097/INF.0b013e3181d7d09c

[6] Sgambatti S., Minamisava R., Bierrenbach A. L. Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance. Vaccine. 2016; 34:663–70. DOI: 10.1016/j.vaccine.2015.12.007

[7] Strachan R., Jaffe A. Assessment of the burden of paediatric empyema in Australia. J. Paediatr. Child Health. 2009; 45:431–6. DOI: 10.1111/j.1440–1754.2009.01533.x

[8] Grijalva C. G., Zhu Y., Nuorti J. P., Griffin M. R. Emergence of parapneumonic empyema in the USA. Thorax. 2011; 66:663–8. DOI: 10.1136/thx.2010.156406

[9] Grijalva C. G., Nuorti J. P., Zhu Y., Griffin M. R. Increasing incidence of empyema complicating childhood communityacquired pneumonia in the United States. Clin. Infect Dis. 2010; 50:805–13. DOI: 10.1086/650573

[10] Byington C. L., Hulten K. G., Ampofo K. Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J. Clin. Microbiol. 2010; 48:520–5. DOI: 10.1128/JCM.01200–09

[11] Hsieh Y. C., Wang C-W., Lai S-H., Lai J-Y, Wong K-S, Huang Y-C. Necrotizing pneumococcal pneumonia with bronchopleural fistula among children in Taiwan. Pediatr. Infect. Dis. J. 2011; 30:740–4. DOI: 10.1097/INF.0b013e31821b10c3

[12] Ramphul N., Eastham K. M., Freeman R., Eltringham G., Kearns A. M., Leeming J. P. Cavitatory lung disease complicating empyema in children. Pediatr. Pulmonol. 2006; 41:750–3. DOI: 10.1002/ppul.20434

[13] McKee A.J., Ives A., Balfour-Lynn I. M. Increased incidence of bronchopulmonary fistulas complicating pediatric pneumonia. Pediatr. Pulmonol. 2011; 46:717–21. DOI: 10.1002/ppul.21396

[14] Lemaitre C., Angoulvant F., Gabor F., Makhoul J., Bonacorsi S., Naudin J. Necrotizing pneumonia in children. Report of 41 cases between 2006 and 2011 in a French tertiary care center. Pediatr. Infect. Dis. J. 2013; 32:1146–9. DOI: 10.1097/INF.0b013e31829be1bb

[15] Sawicki G. S., Lu F. L., Valim C., Cleveland R. H., Colin A. A. Necrotising pneumonia is an increasingly detected complication of pneumonia in children. Eur. Respir. J. 2008; 31:1285–91. DOI: 10.1183/09031936.00099807

[16] Obando I., Valderrabanos E. S., Millan J. A., Neth O. W. Necrotizing pneumonia due to influenza a (H1N1) and communityacquired methicillin-resistant Staphylococcus aureus clone USA300: successful management of the first documented pediatric case. Arch. Dis. Child. 2010; 95:305–6.

[17] Spencer D. A., Thomas M. F. Necrotizing pneumonia in children. Pediatr. Respir. Rev. 2014; 15:240–5.

[18] Jauneikaite E., Tocheva A. S., Jefferies J. M. Current methods for capsular typing of Streptococcus pneumoniae. J. Microbiol. Methods. 2015; 113:41–9. DOI: 10.1016/j.mimet.2015.03.006

[19] Kerem E., Bar Ziv. Y., Rudenski B., Katz S., Kleid D., Branski D. Bacteremic necrotizing pneumococcal pneumonia in children. Am. J. Respir. Crit. Care. Med. 1994; 149:242–4. DOI: 10.1164/ajrccm.149.1.8111589

[20] Chen J., Luo Y., Zhang S., Liang Z., Wang Y., Zhang T. Community-acquired necrotizing pneumonia caused by methicillinresistant Staphylococcus aureus producing Panton-valentine leucocidin in a Chinese teenager: case report and literature review. Int. J. Infect. Dis. 2014; 26:17–21. DOI: 10.1016/j.ijid.2014.02.025

[21] Linares J., Ardunay C., Pallares R., Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin. Microbiol. Infect. 2010; 16:402–10. DOI: 10.1111/j.1469–0691.2010.03182.x

[22] Reinert R. R., Jacobs M. R., Kaplan S. L. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010; 28:4249–59. DOI: 10.1016/j.vaccine.2010.04.020

[23] Dayan G. H., Mohamed N., Scully I. L. Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention. Expert Rev. Vaccines. 2016; 11:1373–92. DOI: 10.1080/14760584.2016.1179583

[24] Schwartz K. L., Nourse C. Panton-valentine leucocidin-associated Staphylococcus aureus necrotizing pneumonia in infants: a report of four cases and review of the literature. Eur. J. Pediatr. 2012; 171:711–7. DOI: 10.1007/s00431–011–1651-y

[25] Gillet Y., Vanhems P., Lina G. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-valentine leucocidin. Clin. Infect. Dis. 2007; 45:315–21. DOI: 10.1086/519263

[26] Loffler B., Hussain M., Grundmeler M. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathogens 2010; 6(1): e1000715.

[27] Shallcross L. J., Fragaszy E., Johnson A. M., Hayward A. C. The role of the Panton-valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. Lancet. Infect. Dis. 2013; 13:43–54. DOI: 10.1016/S1473–3099(12)70238–4

[28] Sicot N., Khanafer N., Meyssonnier V. Methicillin resistance is not a predictor of severity in community-acquired Staphylococcus aureus necrotizing pneumonia – results of a prospective observational study. Clin. Microbiol. Infect. 2013;19: e142–8. DOI: 10.1111/1469–0691.12022

[29] Tong S. Y., Davis J. S., Eichenberger E., Holland T. L., Fowler V. G. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin. Microbiol. Rev. 2015; 28:603–61. DOI: 10.1128/CMR.00134–14

[30] Chatha N., Fortin D., Bosma K. J. Management of necrotizing pneumonia and pulmonary gangrene: a case series and review of the literature. Can. Respir. J. 2014; 21:239–45. DOI:10.1155/2014/864159

[31] Amorim P., Morcillo A. M., Tresoldi A. T., Fraga Ade. M., Pereira R. M., Baract E. C. Factors associated with complications of community-acquired pneumonia in preschool children. J. Bras. Pneumonol. 2012; 38:614–21. DOI: 10.1590/S1806–37132012000500011

[32] Yazer J., Giacomantonio M., MacDonald N., Lopushinsky S. Severe necrotizing pneumonia in a child with pandemic (H1N1) influenza. Can. Med. J. 2011; 183:215–9. DOI: 10.1503/cmaj.100285

[33] Janapatla R. P., Hsu M. H., Hsieh Y. C., Lee H. Y., Lin T. Y., Chiu C. H. Necrotizing pneumonia caused by nanC-carrying serotypes is associated with pneumococcal haemolytic uraemic syndrome in children. Clin. Microbiol. Infect. 2013; 19:480–6. DOI: 10.1111/j.1469–0691.2012.03894.x

[34] Bosch A. A., Biesbroek G., Trzcinski K., Sanders E. A., Bogaert D. Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog. 2013; 9: e1003057. DOI: 10.1371/journal.ppat.1003057

[35] Loizzi M., De Palma A., Pagliarulo V., Loizzi D., Sollitto F. Pulmonary infections of surgical interest in childhood. Thorac. Surg. Clin. 2012; 22:387–401. DOI: 10.1016/j.thorsurg.2012.04.005

[36] Hacimustafaoglu M., Celebi S., Sarimehmet H., Gurpinar A., Ercan I. Necrotizing pneumonia in children. Acta. Paediatr. 2004; 93:1172–7. DOI: 10.1111/j.1651–2227.2004.tb02744.x

[37] Thomas M. F., Wort A., Spencer D. A. Management and complications of pneumonia. Pediatr. Child. Health. 2014;25:172–8. DOI: 10.1016/j.paed.2014.11.004

[38] Sly P. D., Zar H. J. The spectrum of lower respiratory tract illness in children after pneumococcal conjugate vaccination. Am. J. Respir. Crit. Care. Med. 2017; 195:13–5. DOI: 10.1164/rccm.201607–1461ED

[39] Lemaitre C., Angoulvant F., Gabor F., Makhoul J., Bonacorsi S., Naudin J. Necrotizing pneumonia in children. Report of 41 cases between 2006 and 2011 in a French tertiary care center. Pediatr. Infect. Dis. J. 2013; 32:1146–9. DOI: 10.1097/INF.0b013e31829be1bb

[40] De Schutter I., Vergison A., Tuerlinckx D. Pneumococcal aetiology and serotype distribution in paediatric communityacquired pneumonia. PLoS One. 2014; 9: e89013. DOI: 10.1371/journal.pone.0089013

[41] Torrses A., Lee N., Cilloniz C., Vila J., Van der Eerden M. Laboratory diagnosis of pneumonia in the molecular age. Eur. Respir. J. 2016;48:1764–78. DOI: 10.1183/13993003.01144–2016

[42] Murdoch D. R. How to best determine causative pathogens in pneumonia. Pneumonia. 2016; 8:1. DOI: 10.1186/s41479016–0004-z

[43] Brealey J. C., Sly P. D., Young P. R., Chappell K. J. Viral bacterial co-infection of the respiratory tract during early childhood. FEMS Microbiol. Lett. 2015; 362 р.

[44] Vaideeswar P., Bavdekar S. B., Jadhav S. M., Balan.R, Pandit S. P. Necrotizing adenoviral pneumonia: manifestation of nosocomial infection in pediatric intensive care unit. Ind. J. Pediatr. 2008; 75:1171–4. DOI: 10.1007/s12098–008–0177–4

[45] Torrses A., Lee N., Cilloniz C., Vila J., Van der Eerden M. Laboratory diagnosis of pneumonia in the molecular age. Eur. Respir. J. 2016; 48:1764–78. DOI: 10.1183/13993003.01144–2016

[46] Islam S., Calkins C. M., Goldin A. B. The diagnosis and management of empyema in children: a comprehensive review from the APSA outcomes and clinical trial committee. J. Pediatr. Surg. 2012; 47:2101–10. DOI: 10.1016/j.jpedsurg.2012.07.047

[47] Lai S. H., Wong K. S., Liao SL. Value of lung ultrasonography in the diagnosis and outcome prediction of pediatric community-acquired pneumonia with necrotizing change. PLoS One 2015; 10(6): e0130082.

[48] Shaughnessy E. E., Stalets E. L., Shah S. S. Community-acquired pneumonia in the post 13-valent pneumococcal conjugate vaccine era. Curr. Opin. Pediatr. 2016; 28:786–93. DOI:10.1097/MOP.0000000000000428

[49] Izadnegahdar R., Cohen A. L., Klugman K. P., Qazi S. A. Childhood pneumonia in developing countries. Lancet. Respir. Med. 2013; 1:574–84. DOI: 10.1016/S2213–2600(13)70075–4

RIGHTS & PERMISSIONS

Vecherkin V.A., Toma D.A., Ptitsyn V.A., Koryashkin P.V.